Cancer research
Our research generates data from patient samples, such as urine, blood and tissue to better understand who may develop invasive disease, who may forgo invasive treatment and who may respond best to specific therapy; in other words early intervention and personalised medicine (Harrison). The Villar Cortes group particularly focus on the identification of non-conventional metabolites in plasma samples that can be exploited for biomarker discovery in cancer.
The research does not just focus on the cancer and its molecular make up, but also our immunological response (Powis). We develop innovate methodology in digital and molecular pathology, computer vision, and immunology (Harrison, Reynolds, Powis). Our work also identifies novel resistance mechanisms, modes of actions and synergistic combinations of novel drugs being developed for the clinic. Finally, we apply mathematical modelling and machine learning to the large and complex data sets generated to optimise our understanding of disease and to identify novel drug targets (Lynch).
We work with multiple collaborators within the NHS, academia and industry to not only ensure our research is pioneering, but also has strong translatable impact into the clinic.
